Lantheus Holdings Reports Q1 2025 Financial Results

Lantheus Holdings Inc ( (LNTH) ) has released its Q1 earnings. Here is a breakdown of the information Lantheus Holdings Inc presented to its investors.

Lantheus Holdings Inc. is a leading radiopharmaceutical-focused company that provides innovative solutions to enable clinicians to diagnose, treat, and monitor diseases for improved patient outcomes. Headquartered in Massachusetts, Lantheus has been a key player in the radiopharmaceutical industry for nearly 70 years.

In its first quarter of 2025, Lantheus reported a worldwide revenue of $372.8 million, reflecting a modest growth of 0.8% compared to the previous year. The company’s adjusted earnings per share stood at $1.53, slightly down from $1.69 in the same quarter of 2024. Lantheus also announced strategic acquisitions and divestitures aimed at strengthening its portfolio and focusing on its core areas.

Key financial metrics for the quarter included a decrease in GAAP net income to $72.9 million from $131.1 million in the previous year, and a reduction in operating income by 4.3% to $102.1 million. Despite these declines, Lantheus maintained a strong cash position with $938.5 million in cash and equivalents, and generated a free cash flow of $98.8 million. The company also completed the acquisition of Evergreen Theragnostics and is set to finalize the acquisition of Life Molecular Imaging.

Strategically, Lantheus is divesting its SPECT business to focus on its PET radiodiagnostics and microbubbles. The company also announced positive data from pivotal studies of its MK-6240 imaging agent and plans to file a New Drug Application later this year. These moves are expected to enhance Lantheus’ capabilities and expand its product pipeline.

Looking ahead, Lantheus remains committed to driving sustainable growth and delivering long-term value to its shareholders. With a disciplined capital allocation strategy and ongoing investments in innovation, the company is poised to strengthen its leadership in the radiopharmaceutical sector.